Recent Posts
- Eyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022 April 20, 2022
- Eyenovia Announces Poster Presentation at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting April 19, 2022
- Eyenovia Announces Positive Study Results Demonstrating that its Optejet® Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutions to a Level Comparable with Non-Preserved Solutions March 15, 2022
Pipeline and Technology
Corporate Address
Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenoviabio.com
Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia
NewsEyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis
NewsEyenovia To Report Third Quarter 2020 Results
News